+40 264 433427

CASE REPORT

A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy

download Full Article (PDF file)

Tadahisa Inoue, Hitoshi Sano, Takashi Mizushima, Hirotada Nishie, Hiroyasu Iwasaki, Fumihiro Okumura

Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan

http://dx.doi.org/10.15403/jgld.2014.1121.243.ino

ABSTRACT


We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.

Key words: duodenal neuroendocrine carcinoma – amrubicin – chemotherapy.